GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
112 articles in GLP-1 & Metabolic · page 8 of 10
GLP-1s and Exercise: A Better-Together Story
GLP-1 weight loss includes lean mass. Why resistance training changes what kind of weight you lose, and what the trials measured.
Read →GLP-1s in Type 2 Diabetes vs Obesity: Different Goals
Same drug class, different endpoints, doses, and expectations depending on why it was prescribed. How diabetes and obesity use diverge.
Read →Rebound Weight After GLP-1s: What Studies Show
STEP 1's extension found people regained two-thirds of lost weight a year after stopping semaglutide. The numbers and what they mean.
Read →The Incretin Effect, Explained
Why oral glucose triggers far more insulin than the same glucose given intravenously, and what happens to that signal in type 2 diabetes.
Read →GLP-1s and Pancreatitis: What the Data Says
A long-standing concern examined against pooled trial meta-analyses. The signal, if real, looks small — here are the numbers.
Read →GLP-1s and Gastroparesis: Weighing the Risk
Slowed stomach emptying is both the mechanism and the side effect. What cohort data and anesthesia guidance actually show.
Read →GLP-1 Dosing and Titration: Why Slow Wins
Wegovy escalates over 16+ weeks for a reason: slow titration trades a slower ramp for far better tolerability. The evidence.
Read →GLP-1s and Thyroid Cancer: Reading the Black-Box Warning
A 437,000-person BMJ cohort found no clear thyroid-cancer signal. The black-box warning rests on rodent data, not human harm.
Read →GLP-1s and Kidney Outcomes: The FLOW Trial, Explained
FLOW cut serious kidney events 24% in diabetics with chronic kidney disease. What the trial shows, and what it does not show.
Read →How GLP-1, GIP, and Glucagon Differ
Three hormones, three roles — and the logic behind single, dual, and triple agonist drugs. How GLP-1, GIP, and glucagon actually differ.
Read →GLP-1s and PCOS: What the Research Shows
A 2026 meta-analysis of 11 trials found modest BMI gains but low-certainty evidence on PCOS hormones and cycle regularity.
Read →GLP-1 Receptor Agonists in the Brain: Appetite and Beyond
These drugs act centrally, not just in the gut. What that means for appetite, reward, and the side effects people actually feel.
Read →